Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUAZAR AML-001: Oral Azacitidine Maintenance in AML
NCT01757535Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2013
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of CC-486 in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Started Apr 2013; status: completed.
02
Drugs
CC-486
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01757535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01757535.